title: Meningococcal meningoencephalitis after certolizumab pegol treatment in a patient with Crohn's disease.
authors: Shounak
authors: S
authors: Majumder
authors: Anupam
authors: A
authors: Kumar
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D002443:Ceftriaxone / Q000627:therapeutic use; D000068582:Certolizumab Pegol; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects* / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008585:Meningitis, Meningococcal / Q000188:drug therapy / Q000209:etiology*; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D012307:Risk Factors
chemical_list: D000900:Anti-Bacterial Agents; D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D007166:Immunosuppressive Agents; D011092:Polyethylene Glycols; D002443:Ceftriaxone; D000068582:Certolizumab Pegol